All content is for general information only — not medical advice, not a dosing or usage recommendation, and not a claim of efficacy. Many substances are not approved as medicines or are prescription-only; whether possession and use are legal depends on the law of your country of residence and is your own responsibility. myPeptides does not sell or supply any substances — it is an information and organization tool. For health questions, consult a licensed physician or pharmacist.

Peptide register

Every peptide covered here, with its mechanism class, legal status and WADA status. This is a status register, not a shop: no suppliers, no doses, no efficacy claims.

Sort

Class

Legal status

WADA status

Monograph

9 of 73

Cagrilintide

Incretins & metabolicIn clinical development WADA · Prohibited (S0)

Long-acting amylin analogue in phase 3 development; not approved anywhere.

Monograph

Dulaglutide

Incretins & metabolicPrescription medicine

Long-acting GLP-1 receptor agonist fusion protein; approved prescription medicine.

Monograph

Exenatide

Incretins & metabolicPrescription medicine

First licensed GLP-1 receptor agonist; approved prescription medicine since 2005.

Originator products discontinued in the US

Monograph

Liraglutide

Incretins & metabolicPrescription medicine

GLP-1 receptor agonist; approved prescription medicine since 2009.

Monograph

Mazdutide

Incretins & metabolicPrescription medicine

Dual glucagon and GLP-1 receptor agonist; approved as a prescription medicine in China in 2025.

China only

Monograph

Retatrutide

Incretins & metabolicIn clinical development WADA · Prohibited (S0)

Triple GIP, GLP-1 and glucagon receptor agonist in phase 3; not approved anywhere.

Monograph

Semaglutide

Incretins & metabolicPrescription medicine WADA · Monitoring programme (Monitoring 2026)

GLP-1 receptor agonist; approved prescription medicine in the US and the EU.

Monograph

Survodutide

Incretins & metabolicIn clinical development WADA · Prohibited (S0)

Dual glucagon and GLP-1 receptor agonist in phase 3 development; not approved anywhere.

Monograph planned

Tirzepatide

Incretins & metabolicPrescription medicine WADA · Monitoring programme (Monitoring 2026)

Dual GIP and GLP-1 receptor agonist; approved prescription medicine.

Monograph

Take myPeptides with you

Track doses, plans and progress on your phone — end-to-end encrypted.

This article is for informational purposes only and does not replace medical advice. myPeptides gives no dosing recommendations.